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OATP1B1 is an influx transporter known to mediate the uptake of various endogenous compounds and
xenobiotics. Several sequence variations have been discovered in theSLCO1B1 gene encoding OATP1B1.
The aim of this study was to investigate the effects of SLCO1B1 polymorphisms on the pharmacokinet-
ics of atorvastatin in healthy volunteers of Macedonian origin. Twenty three participants, genotyped for
SLCO1B1 c.388A>G, c.521T>C, c.571T>C, c.597C>T, c.1086C>T, c.1463G>C and c.*439T>G poly-
morphisms using TaqMan allelic discrimination assay, ingested a single 80mg dose of atorvastatin. The
plasma concentrations of atorvastatin were measured for 48 h using Tandem Liquid Chromatography-Mass
Spectrometry, LC-MS-MS, and the peak plasma concentration (Cmax), time to peak plasma concentration
(Tmax), elimination half-life (t1/2), constant rate of elimination (kel), mean residence time (MRT, expo), vol-
ume of distribution (Vd/kg), clearance (CL/kg), area under curve AUC0-48h and AUC0-∞ were determined.
Our data confirmed that the SLCO1B1 gene is highly polymorphic, with a frequency of the c.521T>C
single-nucleotide polymorphism (SNP) being the lowest (app. 15%) and of all other SNPs alleles above
40%. Exceptions were c.1463G>C and c.1086C>T SNPs for which variant alleles were not identified.
The strongest correlation was observed between the c.521T>C and c.571T>C SNPs pair. The haplo-
type analysis revealed 10 different haplotypes, with *1J/*1K/*1L being the dominant, with a frequency of
app. 40%. The haplotype *15/*16/*17, containing both variant alleles of the functionally most distinguished
SNPs, c.388A>G and c.521T>C, occurred with a frequency of 13%. However, *15/*16/*17 homozygotes
were not identified in the study group. In this study, no significant differences in the kel, t1/2, Cmax, Tmax,
AUC0-48h, AUC0-∞, MRT expo, Vd and CL between the carriers of different c.388A>G, c.597C>T and
c.*439T>G genotypes were observed. Subject with a variant allele C in the c.521T>C SNP, c.521CC
genotype, had markedly higher values for Cmax and AUC0-48h, 140% and 67%, respectively, in comparison
with the carriers of the c.521TT genotype. Also, the carriers of the variant allele C at c.571T>C SNP, c.571
CC genotype, had 55% and 43% lower mean Cmax and AUC0-48h in comparison with the carrier of c.571TT.
These differences lacked statistical significance due to the size of the sample. In addition, no significant
differences in the pharmacokinetic parameters of atorvastatin between the *15/*16/*17 heterozygotes and
*15/*16/*17 non-carriers were observed. In conclusion, this extensive analysis of the effect of SLCO1B1
polymorphisms on the pharmacokinetic profile of atorvastatin showed that c.521T>C and c.571T>CSNPs
may affect the inter-individual response to atorvastatin. Additional studies, with a large sample size, are
needed to confirm this finding.
1. Introduction
As 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors, statins are widely prescribed for the treatment of
dyslipidemia. Their use also reduces the risk of vascular events
and even the mortality rate. Therefore, statins in conjunction
with lifestyle changes are proposed as a first line treatment in
the primary and secondary prevention of cardiovascular disease
(Expert panel on detection, evaluation, and treatment of high
blood cholesterol in adults 2001).
Among statins, atorvastatin is widely used in the treatment of
hypercholesterolemia to reduce cardiovascular morbidity and
mortality in high risk patients (Pasanen et al. 2007). Compared
to other statins, it causes greater reductions of cholesterol and
triglyceride levels (Jones et al. 1998). However, despite its clin-
ical efficacy, great variability in the clinical response exists and
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the reason for this phenomenon is still not fully understood.
There is evidence that even when the same dose is administered,
the LDL cholesterol serum concentrations can vary largely, from
reduction of only 6% to nearly 62% (Rodrigues et al. 2011).
Apart from intrinsic factors (i.e. genetic variations), variations
in the drug response was shown to be related to extrinsic factors,
such as compliance, time of administration, concomitant medi-
cation, and dietary intake (Thompson et al. 2002; Magee et al.
2010).
Much attention is paid to genetic factors affecting inter-
individual differences in clinical response and there is clear
evidence that adverse effects such as myalgia, myositis, myopa-
thy and even rhabdomyolysis, although rare, are often associated
with increased plasma concentrations caused by a hereditary
difference in Statin pharmacokinetics (Mangravite et al. 2006;
Superko et al. 2012; Postmus et al. 2012; Brunham et al.
2012; Srecko et al. 2012, Zhou et al. 2013a, b; Pasanen et al.
2006b). Several studies in this area point to single-nucleotide
polymorphisms (SNPs) in the gene encoding multiple organic
anion transporting polypeptide 1B1 (OATP1B1), SLCO1B1,
as responsible for the variability of atorvastatin response
(Rodrigues et al. 2011; Pasanen et al. 2007; Thompson et al.
2005; Lee et al. 2010; Lau et al. 2007). OATP1B1, expressed on
the sinusoidal membrane of human hepatocytes, is responsible
for the transport of atorvastatin and its uptake from the sinusoidal
blood into hepatocytes where atorvastatin not only manifests its
pharmacodynamic effect but is metabolized as well (Rodrigues
et al. 2011; Hubacek et al. 2012).
SNPs 388A > G (*1b, rs2306283) and 521T > C (*5, rs4149056)
that encode alanine substitution of valine at amino acid
174 (p.Val174Ala), and amino acid change at position 130
(p.Asn130Asp), respectively, are considered as the most preva-
lent SLCO1B1 variants relevant for the variability of drug
response. The c.388A > G (p.Asn130Asp) variant has been asso-
ciated with increased OATP1B1 transport activity of several
substrate drugs in vitro (Jiake et al. 2011; Michalski et al.
2002; Kameyama et al. 2005) unlike the c.521T > C variant
for which reduced OATP1B1 transport activity in vitro and
increased plasma concentrations of several substrate drugs in
the human body were observed (Kalliokoski et al. 2010; Niemi
2007; Pasanen et al. 2007).
Recent data indicate that the two variants 388A > G and
521T > C are in linkage disequilibrium (LD) and exist in
different SLCO1B1 haplotypes; AT (*1A, reference haplo-
type), GT (*1B), AC (*5) and GC (*15), for c.388A > G
and c521T > C, respectively (Pasanen et al. 2006). Haplo-
types *15 and *5 have been consistently associated with
a decreased transport activity, while controversial results
have been reported for *1B haplotype (Kameyama et al.
2005). In a study of Mwinyi et al. (2004), SLCO1B1*1B
c.388G/c.521T carriers had a higher transport activity than
the carriers of wild-type SLCO1B1*1A c.388A/c.521T. It
was also demonstrated that the SLCO1B1*17 haplotype (g.-
11187G > A, c.388G > A and c.521T > C) was associated with
increased plasma concentrations of pravastatin in humans
(Niemi et al. 2004), while enhanced response to fluvastatin
was confirmed for *14 haplotype (c.388G-c.463A-c.521T)
(Couvert et al. 2008). Similarly, in the study of Pasanen
et al. (2007), the AUC0-48h of atorvastatin was higher in
the c.521TC heterozygotes with *17 and *16 haplotypes
than in the carriers of *15 haplotype. Also, Lee et al.
(2010) reported significantly higher AUC0-∞ for atorvas-
tatin in *15/*15 carriers than in carriers with *1A/*15,
*1B/*15, *1A/*1A, *1A/*1B and *1B/*1B haplotypes. It
was also suggested that the SLCO1B1*15 allele may be
associated with individual differences in the AUC0-∞ of ator-
vastatin.
In our previous work (Daka et al., submitted for publication) we
characterized, for the first time, the diversity of the SLCO1B1
gene in 266 subjects of Macedonian ethnicity and within the
study, the distribution of SCLO1B1 alleles was determined at
7 variant sites (c.388A > G, c.521T > C, c.571T > C, c.597C > T,
c.1086C > T, c.1463G > C and c.*439T > G). Our data confirmed
that SLCO1B1 is highly polymorphic in this ethnic group and
that several variants appear at a high frequency. In addition,
20 different haplotypes were detected, of which the haplotype
*1J/*1K/*1L containing the variant allele C at position c.571 and
referent alleles in other SNPs was the most frequent. Knowing
that SCLO1B1 polymorphism may markedly affect the pharma-
cokinetics of several statins, including atorvastatin, the aim of
this study was to investigate the effects of variant SLCO1B1
genotypes and haplotypes on the pharmacokinetics of atorvas-
tatin in human subjects of Macedonian ethnicity. Together with
the effects of the relevant c.388A > G and c.521T > C SNPs,
the effects of three other SNPs (c.571T > C, c.597C > T and
c.*439T > G), present in the studied population at high frequen-
cies, were also evaluated. At the best of our knowledge, no data
for the effects of these three SNPs on atorvastatin pharmacoki-
netics are available, although their variant alleles can be found
in many haplotypes.
2. Investigations and results
2.1. Genotype and haplotype analysis
Data for the distribution of genotypes and allele frequencies
of SLCO1B1 polymorphisms among 23 healthy volunteers are
presented in Table 1.
The observed genotypes and allelic frequencies of SLCO1B1
polymorphisms did not show significant deviations from the
Hardy-Weinberg equilibrium (p > 0.05). All SNPs, except
c.1463G > C and c.1086C > T occurred at an allele frequency
higher than 15%. Variant alleles of SLCOB1 c.1463G > C and
c.1086C > T polymorphisms were not identified in the study
group. The frequency of the c.521T > C variant allele SNP was
the lowest (15.2%), while the frequencies of all other SNPs
alleles were above 39%, with a frequency of c.571T > C variant
allele being the highest (app.70%).
LD analysis of the single SNPs, quantified by r2 and D’ val-
ues, showed that the most strongly correlated (r2≥0.33) SNPs
pair was c.597C > T/c.388A > G (r2 = 0.571, D’ = 0.792). The
c.521T > C showed the strongest correlation with c.571T > C
(r2 = 0.410, D’ = 1.000) followed by c.597C > T (r2 = 0.306,
D’ = 1.000). Another SNPs pair showing a significant associ-
ation was c.388A > G/c.*439T > G (r2 = 0.309, D’ = 0.636). The
correlation of the most active SNPs pair, c.388A > G/c.521T > C,
was relatively weaker compared to the other SNPs pairs, with
r2 = 0.137 and D’ = 0.700.
The haplotype analysis of the study group revealed ten different
haplotypes (Table 2. Two haplotypes were designated as new.
Seven haplotypes occurred at a frequency greater than 3%. The
most common haplotype in the study group *1J/*1K/*1L had a
frequency of 40.5%. The variant allele G at positions c.388 and
c.*439 existed in five haplotypes, with a frequency between 2%
and 13%, while the variant allele C at position c.571 existed in
four haplotypes that occurred with frequencies between 5.5%
and 40.5%. The frequencies of the haplotypes that included the
variant allele T at c.597, six haplotypes, ranged from 2% to
13% and the same was observed for the frequencies of the two
haplotypes that contained the variant allele C at c.521. Both
variant alleles G and C of the functionally most distinguished
SNPs, c.388A > G and c.521T > C, respectively, were present in
one haplotype, *15/*16/*17, with a frequency of 13% (Table 2).
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Table 1: Distribution of genotype and allele frequencies of SLCO1B1 polymorphisms
Observed frequency n (%) Expected frequency by HWE (%) &p value
Position‡/ dbSNP ID
c.388A > G/rs2306283
AA 8 (34.8) 37.0
AG 12 (52.2) 47.6 0.647874
GG 3 (13.0) 15.3
G allele 18 (39.1)
A Allele 28 (60.9)
c.521T > C rs4149056
TT 17 (73.9) 2.3
CT 5 (21.7) 25.8 0.450052
CC 1 (4.3) 71.9
C allele 7 (15.2)
T allele 39 (84.8)
c.571T > C/rs4149057
CC 10 (43.5) 48.4
CT 12 (52.2) 42.3 0. 265625
TT 1 (4.3) 9.3
C allele 32 (69.6)
T allele 14 (30.4)
c.597C > T/rs229107
CC 9 (39.1) 39.7
CT 11 (47.8) 46.6 0.899371
TT 3 (13.0) 13.7
C allele 29 (63.0)
T allele 17 (37.0)
c.1086C > T/rs57040246
CC 23 (100)
CT 0
TT 0
T allele 0
c.1463G > C/rs59502379
CC 0
CG 0
GG 23 (100)
C allele 0
c.*439T > G/rs4149087
GG 5 (21.7) 20.8
GT 11(47.8) 49.6 0.862216
TT 7(30.4) 29.5
G allele 21(45.7)
T allele 25(54.3)
‡The positions of SNPs are given in relation to the NCBI reference sequences NM 006446.2 (cDNA; c.) with the first nucleotide of the ATG first codon set to 1 and the nucleotide 5’ of ATG set to -1. The
position of c.*439 is given with the first nucleotide 3’ of the stop codon (TAA) set to *1.
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Fig. 1: Mean (± SD) plasma concentrations of atorvastatin after single 80 mg oral
dose of atorvastatin in 23 healthy volunteers in relation to the SLCO1B1
c.388A > G SNP: () c.388AA subjects with genotype (n = 8); () c.388AG
genotype (n = 12); and () c.388GG genotype (n = 3).
2.2. Effects of SLCO1B1 SNPs on the pharmacokinetics
of atorvastatin
The association between the SLCO1B1 genotypes and the phar-
macokinetic profile of atorvastatin is presented in Figs. 1–5
and Table 3. Considering the kel, t1/2, Cmax, Tmax, AUC0-48h,
AUC0-∞, MRT expo, Vd and CL of atorvastatin, statistically
no significant differences in these parameters were observed
between the carriers of different c.388A > G, c.597C > T and
c.*439T > G genotypes. However, noticeable differences in
Cmax, Tmax, AUC0-48h, AUC0-∞, Vd and CL of atorvastatin
between the carriers of c.521CC and c.521TT genotypes and
between the c.571TT and c.571CC genotypes were observed.
The effects of c.521CC and c.571TT genotypes on these phar-
macokinetic parameters could not be effectively analyzed due
to the low number of subjects homozygous for the c.521C and
c.571T alleles.
Fig. 2: Mean (± SD) plasma concentrations of atorvastatin after single 80 mg oral
dose of atorvastatin in 23 healthy volunteers in relation to the SLCO1B1
c.521T > C SNP: () c.521CC subjects with genotype (n = 1); () c.521CT
genotype (n = 5); and () c.521TT genotype (n = 17).
Fig. 3: Mean (± SD) plasma concentrations of atorvastatin after single 80 mg oral
dose of atorvastatin in 23 healthy volunteers in relation to the SLCO1B1
c.571C > T SNP: () c.571CC subjects with genotype (n = 10); () c.571CT
genotype (n = 12); and () c.571TT genotype (n = 1).
Fig. 4: Mean (± SD) plasma concentrations of atorvastatin after single 80 mg oral
dose of atorvastatin in 23 healthy volunteers in relation to the SLCO1B1
c.597C > T SNP: () c.597CC subjects with genotype (n = 9); () c.597CT
genotype (n = 11); and () c.597TT genotype (n = 3).
Fig. 5: Mean (± SD) plasma concentrations of atorvastatin after single 80 mg oral
dose of atorvastatin in 23 healthy volunteers in relation to the SLCO1B1
c.*439G > T SNP: () subjects with c.*439GG genotype (n = 5); ()
c.*439GT genotype (n = 11); and () c.*439TT genotype (n = 7).
In the subjects with the SLCO1B1 c.388GG genotype (n = 3), the
mean Cmax was app. 45% and 59% higher than the mean Cmax
in the subjects with the c.388AA (n = 8) and c.388AG (n = 12)
genotypes, p = 0.702 (Table 3). Similarly, a slightly higher mean
value for the AUC0-48h in the subjects with the c.388GG geno-
type was detected, 15% and 13% higher in comparison with the
AUC0-48h in the carriers of c.388AA and c.388AG genotype,
respectively, p = 0.977.
Considering the pharmacokinetic parameters of atorvastatin in
carriers of different c.521T > C genotypes, the mean Cmax and
AUC0-48h were app. 42% higher in the carriers of the c.521CT
genotype (n = 5) compared to the carriers of the c.521TT geno-
type (n = 17), p = 0.157 and p = 0.112, respectively. Cmax and
AUC0-48h of atorvastatin in c.521CC genotype were app. 140%
and 67%, respectively, higher than the mean Cmax and AUC0-48h
in the carriers of the c.521TT genotype and app. 69% and 18%
higher than the mean values of the corresponding parameters in
the subjects with the c.521CT genotype, p = 0.057 and 0.138,
respectively. Despite the fact that a subject with c.521CC geno-
type had markedly higher values for Cmax and AUC0-48h in
comparison with the subjects carrying c.521CT and c.521TT
genotypes, these differences lack statistical significance due to
the size of the sample.
Similar findings were observed when comparing the pharma-
cokinetic parameters of atorvastatin between the carriers of
different c.571T > C genotypes. Namely, the Cmax in the c.571TT
genotype was app. 120% higher than the mean Cmax in the
c.571CC and app. 114% higher than the mean Cmax in c.571CT
carriers, p = 0.164. In addition, the AUC0-48h of a c.571TT car-
rier was app. 75% and 27% higher than the mean AUC0-48h of
the c.571CC and c.571CT carriers, respectively, p = 0.149.
The mean Cmax in the carriers of the c.597TT genotype (n = 3)
was app. 88% and 74% higher than the one in the c.597CT
(n = 11) and c.597CC carriers (n = 9), respectively, p = 0.134.
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Table 2: Alignment and frequencies of SLCO1B1 haplotypes in the study group
SLCO1B1 haplotype c.388A > G c.521T > C c.571T > C c.597C > T c.1086 C > T c.1463 G > C c.*439 T > G Haplotypes found
Reference A T T C C G T N % 95%Cl
*1J/*1K/*1La C 18 40.5 0.425–2.355
*15a/*16b/*17c G C T G 6 13.0 0.295–3.390
*1J/*1K/*1La C G 6 12.6 0.290–3.451
*18d/Newe G C T G 5 10.9 0.268–3.733
*1B/*1Fa/Newh G G 3 6.5 0.190–5.266
*18g/Newf G C T 2 5.5 0.167–5.986
*1Aa/Newh/*1E i 1 3.4 0.105–9.500
*20j/*21k/Newh G T 1 2.7
New C T 1 2.2
New T G 1 2.2
The gray boxes denote reference sequence
a The name includes the presented sequence of the SNPs investigated in the actual study and referent alleles of the additional SNPs investigated in the study of Pasanen et al. (2006) (at positions g.-11187,
g.-11110, g.-10499, c.411, c.463 and c.1929)
b,c,d,g,i,j,k The haplotype name includes a sequence of the SNPs investigated in the actual study and referent alleles in other SNPs investigated in the cited study (Pasanen et al. 2006), except at the following
positions b: g.-10499; c: g.-11187; d: c.411 and c.463; g: c.411 and c.463; i: g.-11110; j: c.1929 and k; g.-11187 and c.1929, where variant alleles exist.
e,h,f The haplotype is assigned as new by Pasanen et al. (2006), having the same sequence of the SNPs investigated in the actual study and referent alleles at other SNPs investigated in the cited study (Pasanen
et al. 2006), except at the following positions e: g.-11110, c.411 and c.463; h: g.-11187 and f. c.411, c.463 and c.1929, where variant alleles exist.
Insignificantly higher mean value for the mean AUC0-48h in
the carriers of the c.597TT genotype was observed in compar-
ison with the mean values of the corresponding parameter in
the c.597CT and c.597CC carriers (15% and 31%, respectively,
p = 0.611) (Table 3).
As mentioned previously, there was no statistically significant
association between the pharmacokinetic parameters of ator-
vastatin and c.*439T > G SNP. The difference in Cmax between
the carriers of different SLCO1B1 c.*439T > G genotypes was
between 13% and 20% (p = 0.603), while for the mean AUC0-48h,
differences of app. 30% were observed (p = 0.371).
In addition, we investigated the effects of the SLCO1B1
haplotypes found in our study group (with a frequency above
5.5%) on the pharmacokinetic parameters of atorvastatin
(Table 4). Participants were assigned to one of two groups
based on their SLCO1B1 genotype: *15/*16/*17 non-carriers
(n = 13) and *15/*16/*17 heterozygotes (n = 5). *15/*16/*17
homozygotes were not identified in the study. *15/*16/*17
haplotype was chosen as a carrier of the variant c.521C allele,
known to affect the pharmacokinetics of statins. Thus, the
group 1 (n = 13) included: *1J/*1K/*1L/*1J/*1K/*1L (n = 6),
*1J/*1K/*1L/*18/new (n = 3), *1J/*1K/*1L/*18/new (n = 1),
*1J/*1K/*1L/*1B/*1F/new (n = 1), *1J/*1K/*1L/*1B/*1F/new
(n = 1) and *1B/*1F/new/18/new (n = 1), containing
(c.521TT, c388GG + AG + AA, c.571CC + CT, c.597CC + CT
and c.*439TT + GT + GG). In the group 2 (n = 5),
*1J/*1K/*1L/*15/*16/*17 (n = 2), *1J/*1K/*1L/*15/*16/*17
(n = 1), *15/*16/*17/*18/new (n = 1), *15/*16/*17/*18/new
(n = 1) were included, containing (c.521CT, c.388AG + GG,
c.571CT, c.597TT + CT and c.*439GG + GT). No significant
differences in the pharmacokinetic parameters of atorvastatin
between the *15/*16/*17 heterozygotes and *15/*16/*17
non-carriers were observed (Table 4). However, the mean value
of Cmax was higher in the group of *15/*16/*17 heterozygotes
(app. 22%, p = 0.375) as well as the mean values of AUC0-48h
(app. 37%, p = 0.136) and AUC0-∞ (app. 38%, p = 0.127).
3. Discussion
The search for potent and efficacious inhibitors of the enzyme
HMG-CoA reductase in the 1980 s resulted in the discov-
ery and development of atorvastatin (Roth et al. 2002). It
is still among the top 20 prescribed medicines in the USA
(www.drugs.com/stats/top100/sales) and top 10 in the Republic
of Macedonia, with the highest sales (www.fzo.org.mk). There
is evidence for a large variability in the individual response and
occurrence of adverse effects, such as myopathy, and even rhab-
domyolysis. As one of the reasons for adverse effects, hereditary
differences in atorvastatin pharmacokinetics have been pointed
out, including the effects of SLCO1B1 SNPs on atorvastatin
pharmacokinetics (Pasanen et al. 2007). Thus, the aim of this
study was to compare the effects of different SLCO1B1 SNPs
and their haplotypes on the pharmacokinetic profile of atorvas-
tatin in 23 subjects of Macedonian origin. At the best of our
knowledge, this study is the first that has investigated the effects
of the SLCO1B1 c.571T > C, c.597C > T and c.*439G > T on
the pharmacokinetic parameters of atorvastatin and the first one
in which the effects of the most active SNPs, c.388A > G and
c.521T > C SNPs, were evaluated in the Macedonian subjects as
well.
Our data confirmed that SLCO1B1 is highly polymorphic and
that several variants appear at a high frequency. These results
are in consistency with the allele frequencies for the same SNPs
found in Caucasians of different ethnic background (Pasanen
et al. 2008; Mwinyi et al. 2004; 2008) and in our previous
study, in which genotype distribution and allele frequencies of
SLCO1B1 polymorphisms in a large sample of 266 subjects
of Macedonian origin were evaluated (Daka et al. submitted
for publication). The results for the association between the
SNPs pairs as well as the results pointing to the frequencies of
the most common SLCO1B1 haplotypes present in the study
group, *IJ/*IK/*IL followed by *15/*16/*17, containing the
variant alleles at positions c.388A > G, c.521T > C, c.597C > T
and c.*439T > G were very similar to those of our previous
study (Daka et al. submitted for publication). Thus, we con-
sider the group of 23 subjects as a representative sample of the
Macedonian population.
Current knowledge suggests that the SLCO1B1 polymorphisms
may have particularly important effects on the pharmacokinetic
profile of atorvastatin and the studies are mainly focused on the
influence of c.521 T > C polymorphism. In this study, higher
Cmax, AUC0-48h, AUC0-∞, MRTexpo and lower Tmax, Vd and CL
for atorvastatin in SLCO1B1 c.521CC and c.571TT homozy-
gotes were observed in comparison with the other genotype
groups of the c.521T > C and c.571T > C SNPs. Same results
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Table 3: Pharmacokinetic parameters of a single 80mg oral dose of atorvastatin in relation to SLCO1B1 polymorphisms in the
study group
SLCO1B1 Cmax Tmax t1/2 AUC 0-48h AUC 0-∞ Vd area/kg CL area/kg MRTexpo
genotype (ng mL-1) (h) (h) (ng h mL-1) (ng h mL-1) (L kg-1) (L h-1 kg-1) (h)
c.388A > G
c.388AA
(n = 8)
46.33 ± 24.17 0.69
(0.5–1.00)
9.63 ± 2.84 205.42 ± 52.20 209.64 ± 52.93 82.98 ± 38.43 5.91 ± 2.10 13.89 ± 4.10
c.388AG
(n = 12)
42.16 ± 20.25 0.75
(0.5–1.5)
9.66 ± 2.37 208.37 ± 104.71 212.84 ± 106.54 94.10 ± 49.53 6.83 ± 3.66 13.93 ± 3.42
c.388GG
(n = 3)
66.94 ± 48.55 0.87
(0.5–1.25)
8.05 ± 0.92 235.97 ± 174.49 241.90 ± 179.93 72.65 ± 47.78 6.53 ± 4.86 11.61 ± 1.32
c.521T > C
c.521TT
(n = 17)
40.20 ± 18.62 0.68
(0.5–1.0)
9.40 ± 2.20 188.79 ± 77.67 192.71 ± 79.08 94.71 ± 45.27 6.95 ± 3.07 13.57 ± 3.18
c.521CT
(n = 5)
57.11 ± 30.51 1.02
(0.5–1.5)
9.55 ± 3.7 267.79 ± 113.31 274.88 ± 115.82 67.94 ± 37.14 5.16 ± 3.25 13.78 ± 5.34
c.521CC
(n = 1)
96.62 0.5 10.86 315.61 319.28 56.09 3.58 15.67
c.571T > C
c.571CC
(n = 10)
43.84 ± 21.90 0.63
(0.5–1.00)
9.39 ± 2.51 179.93 ± 63.96 183.37 ± 65.00 98.32 ± 48.83 7.24 ± 3.42 13.55 ± 3.63
c.571CT
(n = 12)
45.18 ± 21.83 0.87
(0.5–1.5)
9.22 ± 2.39 249.15 ± 109.23 254.94 ± 111.21 73.39 ± 39.45 5.50 ± 2.72 13.30 ± 3.45
c.571TT
(n = 1)
96.62 0.5 10.86 315.61 319.28 56.09 3.58 15.67
c.597C > T
c.597CC
(n = 9)
44.10 ± 23.70 0.68
(0.5–1.0)
9.65 ± 2.69 199.90 ± 51.76 204.08 ± 52.22 85.49 ± 38.19 6.04 ± 2.01 13.92 ± 3.88
c.597CT
(n = 11)
40.89 ± 12.51 0.79
(0.5–1.5)
9.24 ± 2.38 228.76 ± 117.26 233.79 ± 119.43 86.33 ± 52.65 6.45 ± 3.83 13.33 ± 3.43
c.597TT
(n = 3)
76.83 ± 38.37 0.75
(0.5–1.25)
8.99 ± 1.75 262.51 ± 131.67 267.69 ± 134.85 67.13 ± 35.11 5.55 ± 3.83 12.97 ± 2.53
c.*439T > G
c.*439GG
(n = 5)
42.02 ± 21.10 0.93
(0.5–1.5)
8.52 ± 1.75 195.26 ± 94.03 199.00 ± 94.88 83.45 ± 36.35 6.70 ± 2.65 12.29 ± 2.52
c.*439GT
(n = 11)
50.45 ± 26.23 0.77
(0.5–1.25)
9.85 ± 2.08 252.12 ± 113.09 257.71 ± 115.32 82.67 ± 52.64 5.81 ± 3.85 14.21 ± 3.00
c.*439TT
(n = 7)
44.59 ± 23.11 0.57
(0.5–0.67)
9.22 ± 2.08 193.53 ± 59.09 197.46 ± 60.09 84.81 ± 40.36 6.37 ± 2.28 13.30 ± 3.00
Data are presented as mean ± SD; tmax data are represented as the median (range). AUC0-∞, area under the plasma concentration-time curve from 0 h to infinity; AUC0-48 h, area under the plasma
concentration-time curve from 0 to 48 h; Cmax, peak plasma concentration; t1/2, elimination half- life; Tmax, time to Cmax; Vdarea/kg, weight-adjusted volume of distribution; Clarea/kg, weight-adjusted
clearance.
were also obtained in the study of Pasanen et al. (2007), in which
subjects with SLCO1B1 c.521CC genotype (n = 4) had signif-
icantly larger (144%) mean AUC0-48h than the subjects with
c.521TT (reference) genotype (n = 16) and 61% larger than the
subjects with c.521TC genotype (n = 12). These findings sup-
port the idea that impaired (reduced) OATP1B1 function could
theoretically reduce the clearance of atorvastatin, because of
the decreased entry into the liver, the main site of atorvastatin
metabolism and elimination (Pasanen et al. 2007). Several clini-
cal studies have also demonstrated that subjects, who are carriers
of SLCO1B1 521C allele, had increased plasma concentrations
of other OATP1B1 substrates (e.g. pravastatin and repaglinid)
compared to the subjects who were wild type homozygotes
(Aquilante et al. 2008; Kivisto et al. 2007; Niemi et al. 2005;
Kalliokoski et al. 2008). To our knowledge, no data for the
effect of the c.571T > C SNP on the pharmacokinetics of atorvas-
tatin have been reported so far. Two studies, involving healthy
Chinese volunteers, report for lack of significant effect on sim-
vastatin (n = 12) and pitavastatin (n = 17) pharmacokinetics by
SLCO1B1 c.571T > C. The same was obtained for the SLCO1B1
c.597C > T (Chou et al. 2013 a,b).
In the previous studies it was reported that the SLCO1B1*15
variant (c.388G and c.521C) reduced the transport activity of
OATP1B1 and had an important effect on the atorvastatin sys-
temic exposure and elimination (Nizhizato et al. 2010; Lee et al.
2010; Rodrigues et al. 2011; Pasanen et al. 2007). Therefore, one
expected that the group of *15/*16/*17 heterozygotes, which
included subjects with c.521CT genotype (group 2), would have
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larger AUC0-48h for atorvastatin compared to the AUC0-48h of
the *15/*16/*17 non-carrier group that included subjects with
c.521TT (group 1). So, the larger mean AUC0-48h and AUC0-∞
and lower Vd and CL, observed in the study of the group of
15/*16/*17 heterozygotes, can be explained with the decreased
activity of c.521C variant allele present in this group.
In conclusion, this study provides an valuable analysis of the
effect of SLCO1B1 variant genotype and haplotype distribution
on the pharmacokinetic profile of atorvastatin in individuals
of Macedonian origin. SLCO1B1 c.521T > C and c.571T > C
SNPs investigated in this study affected the pharmacokinetic
parameters of atorvastatin. The lack of statistically significant
association between these SLCO1B1 polymorphisms and the
pharmacokinetic parameters of atorvastatin may be due to the
size of the sample and low number of individuals homozygous
for the rare c.521C variant allele included in the study. Addi-
tional studies, with a larger sample size are needed to confirm
the influence of the SLCO1B1 polymorphisms on atorvastatin
pharmacokinetics.
4. Experimental
4.1. Subjects, genotyping and haplotype analysis
A total of 23 young Caucasian male healthy volunteers (average age 22 ± 4,
BMI 26.33 kg/m2, Macedonian ethnic origin) selected based on their med-
ical history, physical examination, 12-led electrocardiogram (ECG) and
routine clinical laboratory tests and urinary drug screen participated in the
study. All participants were non-smokers. Subjects were not allowed to take
any alcohol and grapefruit-containing foods or xanthine-containing bever-
ages 48 h before and 96 h after the drug administration. The subjects did
not receive any other medication at least 2 weeks prior to the atorvastatin
administration. Subjects with a history of a significant allergic reaction to
any drug, an immunosuppressive condition, malignancy within the past 5
years, significant blood loss within 8 weeks prior to the initiation of the
study, diseases of the gastrointestinal tract, liver, kidneys or any other con-
ditions known to interfere with the absorption, distribution, metabolism or
elimination of drugs were excluded from the study. Individuals with active
drug or alcohol abuse in the past or consumption of large quantities of coffee
or tea were also excluded. Serology screening tests for hepatitis B and C
and HIV, urine drug screening and alcohol breath tests were negative for all
subjects. No concomitant diseases were reported in any of the subjects as
well as previous uptake of medications.
The participants were allocated into groups according to the genotype and
haplotype data for SLCO1B1 SNPs (Table 1 and Table 2). For genotyping,
three mL venous blood samples drawn with ethylenediamintetraacetic acid
(EDTA) as anticoagulant were collected and stored at 4 ◦C prior to DNA
isolation. DNA isolation was performed at the Center for Biomolecular
Pharmaceutical Analyses, UKIM-Faculty of Pharmacy, Republic of
Macedonia, using Qiagen Qiamp DNA Blood kit (Qiagen Gmbh, Hilden,
Germany) according to the manufacturer’s protocol. The samples were
kept at -20 ◦C until further analysis. The SLCO1B1 SNPs to be genotyped
were selected on the basis of literature data (Rodrigues et al. 2011; Pasanen
et al. 2006; Santos et al. 2012; Xu et al. 2007) and a previous study in
which 266 subjects were included (Daka et al. submitted for publication).
Thus, the following variants in the SLCO1B1 gene were analyzed:
c.388A > G (Asn130Asp, rs2306283), c.521T > C (Val174Ala, rs4149056),
c.571T > C (Leu191Leu, rs4149057), c.597C > T (Phe199Phe, rs2291075),
c.1086C > T (Tyr362Tyr, rs57040246), c.1463G > C (Gly488Ala,
rs59502379), c.*439T > G (rs4149087) using TaqMan allelic discrimi-
nation assay (Applied Biosystems, Foster City, CA, USA). Polymerase
chain reaction was performed on the Real-Time PCR system Mx3005P
(Stratagene, La Jolla, CA, USA) using TaqMan genotyping protocols
(TaqMan®Drug Metabolizing assay; Applied Biosystems Foster City, Ca,
USA) in total volume of 12.5L under the following conditions: one cycle
of 2 min at 50 ◦C, one cycle of 10 min at 95 ◦C, and 50 cycles of 15 s at
92 ◦C and 1 minute at 60 ◦C.
The study samples alleles and genotype frequencies were estimated with a
gene counting method. The agreement with Hardy-Weinberg Equilibrium
(HWE) of the observed genotypic distribution for the SLCO1B1 gene was
tested with the Chi-square test. Linkage disequilibrium (LD) for each pair
of SNPs was quantified (correlation r2 and D’ values) to find haplotypes
in the study group. For the analysis of LD, haplotype construction and
genetic association at polymorphism loci, SHEsis software platform was
used (http://analysis2.bio-x.cn/myAnalysis.php) (Shi et al. 2005). The hap-
lotypes are presented with their previously assigned names, as cited in the
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study of Pasanen et al. (2006) in which allelic frequencies at 11 variant sites
were determined (g.11187G > A, g.11110T > G, g.10499A > C, c.388A > G,
c.411G > A, c.463C > A, c.521T > C, c.571T > C, c.597C > T, c.1929A > C
and c.*439T > G). Considering that five of these SNPs and two other SNPs
have been analyzed in the present investigation, one haplotype has several
names and there are haplotypes that we designated as new.
4.2. Study design
The study was conducted in accordance with the ethical principles of
the Declaration of Helsinki and the International Conference on Har-
monization (ICH) Note for Guidance on Good Clinical Practice (GCP)
(CPMP/ICH/135/95) and with applicable local legal requirements. All par-
ticipants received oral and written information and gave a written informed
consent before entering the study. The final clinical trial protocol as well
as the informed consent and other information that required pre-approval
were reviewed and approved by the Independent Ethics Committee accord-
ing to the specifications outlined in the applicable regulations. After a night
fasting, the participants received a single dose of 80 mg atorvastatin (from
the same producer), orally with 200 ml water at 08:00. Standard warm meal
was served four hours after the ingestion of atorvastatin and a standard light
meal after 7 and 10 hours. Blood samples (5-10 ml each) were drown before
the administration of the agent and 0.167, 0.333, 0.5, 0.667, 0.833, 1, 1.25,
1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 and 48 h after the placement
of atorvastatin in tubes that contained EDTA and stored on ice immediately
after sampling. Within 30 min from the blood sampling, the plasma was
separated and stored at -70 ◦C until analysis.
4.3. Determination of plasma drug concentrations
Tandem Liquid Chromatography/Mass Spectrometry LC-MS-MS (Shi-
madzu LC-30 paired with Nexera Shimadzu LCMS 8030 triple quadruple
mass spectrometer ESI interface) was used to determine the concentration
of atorvastatin in the samples, with a method previously described by Pasa-
nen et al. (2007). In brief, chromatography was performed on a Symetry C8
column (50 x 2.1 mm, 3.5m, Waters, Milford, Massachusetts, USA) using
a gradient of 10 mmol/L ammonium acetate (pH 4.95) and acetonitrile. The
ion transitions monitored were mass-to-charge ratio (m/z) 559 to m/z 250.
Data processing was carried out with software Rapidtrace V 2.0.
4.4. Pharmacokinetics and statistical analysis
The pharmacokinetic parameters were calculated with the non-compartment
analysis of serum concentration curve versus time using PK Solutions 2.0
software (copyrighted © 1997-2009, Summit Research Services, USA).
Cmax, time to Cmax (Tmax), elimination half-life (t1/2), constant rate of
elimination (kel), mean residence time (MRT, expo), volume of distri-
bution (Vd/kg), clearance (CL/kg) and area under curve AUC0-48h and
AUC0-∞ were calculated for atorvastatin. The terminal log-linear part of
each concentration-time curve was identified visually, and the elimination
rate constant (kel) was determined from ln-transformed data with a linear
regression analysis. The t1/2 was calculated with the equation t1/2 = ln2/kel.
The AUC values were calculated according to the combination of the lin-
ear and long-linear trapezoidal rules, with extrapolation to infinity, when
appropriate, by dividing the last measured concentration by kel.
The results for the pharmacokinetic parameters are expressed as mean ± SD
in the text and tables. All data were analyzed with the statistical program
IBM SPSS 19.0. The pharmacokinetic variables of atorvastatin between the
genotype groups of SLCO1B1 SNPs were compared using the analysis of
variance and independent t test. Homogeneity of variance was tested using
Levene’s Test of Equality. Post hoc testing was done with the Games-Howell
test. Compatibility of the residuals with normal distribution was assessed
with the Shapiro-Wilk test. When appropriate, the data were logarithmically
transformed before the analysis or analyzed with the Kruskall-Wallis test
with a posteriori testing with the Mann-Whitney U-test. Differences were
considered statistically significant when p was below 0.05.
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